# A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

> **NCT01863953** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 112 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Fixed-Combination Bimatoprost/Brimonidine
- **DRUG:** Bimatoprost Ophthalmic Solution 0.01%
- **DRUG:** Vehicle Ophthalmic Solution
- **DRUG:** Brimonidine Tartrate Ophthalmic Solution 0.2%

## Key facts

- **NCT ID:** NCT01863953
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01863953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01863953, "A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01863953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*